계명대학교 의학도서관 Repository

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes

Metadata Downloads
Author(s)
Ji-Hyun KimJi-Hyun AhnSoo-Kyung KimDae-Ho LeeHye-Soon KimHo-Sang ShonHyun-Jeong JeonTae-Hwa KimYong-Wook ChoJae-Taek KimSung-Min HanChoon-Hee ChungOhk-Hyun RyuJae-Min LeeSoon-Hee LeeMin-Jeong KwonTae-kyun KimIl-Seong NamgoongEun-Sook KimIn-Kyung JungSung-Dae MoonJe-Ho HanChong-Hwa KimEun-Hee ChoKi-Young KimHee-Baek ParkKi-Sang LeeSung-Woo LeeSang-Cheol LeeCheol-Min KangByung-Sook JeonMin-Seop SongSeung-Baik YunHyung-Keun ChungJong-Ho SeongJin-Yi JeongBong-Yun Cha
Keimyung Author(s)
Kim, Hye Soon
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Diabetes Investigation
Issued Date
2015
Volume
6
Issue
2
Keyword
AcarboseLong-acting insulinType 2 diabetes
Abstract
Aims/Introduction:

Early initiation of basal insulin therapy is recommended for normalizing fasting blood glucose in type 2 diabetes mellitus. However, basal insulin treatment might not adequately control postprandial glucose levels. The present study evaluated whether the combination of the α-glucosidase inhibitor, acarbose, and basal insulin improved blood glucose control under daily-life treatment conditions in a large sample of Korean patients.


Materials and Methods:
The present study was a multicenter, prospective, observational study under daily-life treatment conditions. A total of 539 patients with type 2 diabetes who were treated with basal insulin and additional acarbose were enrolled and followed up for 20 weeks. Changes in hemoglobin A1c, fasting and postprandial blood glucose were evaluated at baseline and at the end of the observation period. The physician and patient satisfaction of the combination treatment and safety were assessed.


Results:

Hemoglobin A1c decreased by 0.55 ± 1.05% from baseline (P < 0.0001). Fasting and postprandial blood glucose levels were reduced by 0.89 ± 3.79 and 2.59 ± 4.77 mmol/L (both P < 0.0001). The most frequently reported adverse drug reactions were flatulence (0.37%) and abnormal gastrointestinal sounds (0.37%), and all were mild in intensity and transient. In the satisfaction evaluation, 79.0% of physicians and 77.3% of patients were ‘very satisfied’ or ‘satisfied’ with the combined basal insulin and acarbose therapy.


Conclusions:

Combination therapy of basal insulin and acarbose in patients with type 2 diabetes improved glucose control, and had no drug-specific safety concerns, suggesting that the treatment might benefit individuals who cannot control blood glucose with basal insulin alone.
Keimyung Author(s)(Kor)
김혜순
Publisher
School of Medicine
Citation
Ji-Hyun Kim et al. (2015). Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. Journal of Diabetes Investigation, 6(2), 219–226. doi: 10.1111/jdi.12261
Type
Article
ISSN
2040-1116
DOI
10.1111/jdi.12261
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34022
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.